Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) were down 5.1% during trading on Monday . Finally, Leerink Partnrs raised shares of Protagonist Therapeutics to a “strong-buy” rating in a research report on Friday, September 12th. Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. Protagonist Therapeutics Company Profile(Get Free Report)Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. Featured ArticlesReceive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.